Former Officer Files to Sell Additional $1.6M in Stock, Extending Recent Sales Pattern
OLMA has more than doubled off its 52-week low of $2.86.
Summary
A former officer of Olema Pharmaceuticals has filed to sell an additional $1.6 million in company stock, continuing a pattern of significant insider selling.
Key Events · Ownership and Investor Activity · OLMA
-
Proposed Stock Sale
A former officer, Shane William Charles Kovacs, intends to sell 100,000 shares of common stock, valued at approximately $1.61 million.
-
Continuation of Selling Pattern
This filing extends a recent trend of significant share dispositions by the same former officer, who has sold over $10 million in stock over the past three months.
-
Timing with Earnings Report
The intent to sell comes on the same day the company reported strong Q4 and full-year 2025 financial results, including a robust cash position.
Analysis · OLMA · Life Sciences
This Form 144 filing indicates a former officer's intent to sell an additional $1.6 million worth of Olema Pharmaceuticals stock. This transaction continues a pattern of significant share dispositions by this individual, Shane William Charles Kovacs, who has already sold over $10 million in the past three months. While the company reported strong financial results and pipeline progress today, the ongoing insider selling could signal a lack of long-term conviction or a need for liquidity, potentially offsetting some positive sentiment from the earnings report.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OLMA was trading at $16.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.86 to $36.26. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.